h lundbeck as
Otsuka, Lundbeck Present Lu AE58054 Phase II Data For Alzheimer’s Disease
H. Lundbeck A/S and Otsuka Pharma announced Phase II clinical data on their Lu AE58054 investigational drug for moderate Alzheimer’s disease.
Lundbeck Launches Antidepressent Lexapro In Japan
Lexapro® - the most prescribed branded antidepressant in the world - has been launched in Japan by H. Lundbeck A/S and its partners, Mochiba and Mitsubishi Tanabe Pharma.
Lundbeck And Takeda Initiate Phase III Study For Depression Drug
Takeda and H. Lundbeck A/S announced yesterday the initiation of a phase III clinical trial in Japan for Lu AA21004 in patients with major depressive disorder.
